Gustavo is a seasoned biopharmaceutical executive who joined Amcyte Pharma in 2020. For 12 years prior, he was at AGC Biologics (former CMC Biologics), where he most recently served as Chief Executive Officer. From 1994 to 2008, Dr. Mahler held senior management positions at Bayer Healthcare in US, Europe and Latin America. He currently is venture partner at Dynamk Capital and serves on the board of directors for AGC Biologics, Absci and Life Science Washington. Dr. Mahler received a PhD in Biochemistry from the University of Buenos Aires, a MBA from the UNED of Madrid and Executive Leadership Certification from MIT Sloan.
Claudia Zylberberg, Ph.D., is a leader in regenerative medicine, with more than 30 years of experience in the field. She is the founder and CEO of Akron Biotechnology, an innovative company that develops, manufactures and markets ancillary materials and novel products/tools under cGMP compliance for tissue, cell and gene therapies. She holds numerous patents and has developed several patent-pending platform technologies in cryopreservation, novel formulations and more. She has authored/co-authored peer-reviewed publications and has received grants from the NIH and Department of Defense, among others. Claudia has also authored a children’s book titled You’re Full of Genes, which introduces youths to genetic concepts in an interactive format.
Before starting Akron, Claudia co-founded AssureImmune, an adult stem cell bank, and, in her early years, worked at Nabi Biopharmaceuticals, specializing in human plasma-derived products. Her experience in product development and protein manufacturing has been instrumental in the development of key materials to accelerate the regenerative medicine industry. Claudia co-founded the Standards Coordinating Body (SCB) and is a board member of numerous industry boards and advisory committees. With a doctorate in immunology and background in hematology, Dr. Zylberberg is passionate about the continued growth of the cell therapy industry.
Jorge Cassará leads the biotech and respiratory business at Laboratorio Pablo Cassará, a pharmaceutical company with multiple biosimilars in the market and presence in 25 countries. Under his leadership the company has developed and successfully launched an entire line of recombinant ancillary materials and novel formulations for cell therapy applications. In his current position he also lead several innovative projects to commercialization including Neokit, a novel COVID-19 isothermal PCR diagnostic test. Jorge holds a degree on Chemistry from the University of Buenos Aires.